, 2009Oct, Vol 175, 337-344; see record 2009-17802-007). In the article, scoring instructions in the MoCA Assessment subsection of the Method section included an erroneous parenthetical statement: "(31 if the patient is age 12 or younger)." This statement should have read "(with one point added if the patient has 12 years or fewer of formal education)." This error does not reflect how assessment data were collected in the study and does not affect the results or the conclusions drawn from the data. (The following abstract of the original article appeared in record 2009-17802-007). To date, there has not been a time-efficient and resource-conscious way to identify cognitive impairment in patients with substance use disorders (SUDs). In this study, we assessed the validity, accuracy, and clinical utility of a brief (10-min) screening instrument, the Montreal Cognitive Assessment (MoCA), in identifying cognitive impairment among patients with SUDs. The Neuropsychological Assessment Battery-Screening Module, a 45-min battery with known sensitivity to the mild to moderate deficits observed in patients with SUDs, was used as the reference criterion for determining agreement, rates of correct and incorrect decision classifications, and criterion-related validity for the MoCA. Classification accuracy of the MoCA, based on receiver operating characteristic (ROC) analysis, was strong, with an area under the ROC curve of 0.86, 95% confidence interval 0.75, 0.97. The MoCA also showed acceptable sensitivity (83.3%) and specificity (72.9%) for the identification of cognitive impairment. Using a cutoff of 25 on the MoCA, the overall agreement was 75.0%; chance-corrected agreement (kappa) was 41.9%. These findings indicate that the MoCA provides a time-efficient and resource-conscious way to identify patients with SUDs and neuropsychological impairment, thus addressing a critical need in the addiction treatment research community. (PsycInfo Database Record (c) 2026 APA, all rights reserved).
A Mon, study studied this question.